CSBR Financial Facts

Loss before provision for income taxes: -2.53M
Cost of translational oncology solutions: 2.05M
See Full Income Statement

Total current assets: 6.44M
Deferred revenue: 2.7M
See Full Balance Sheet

Champions Oncology, Inc. (CSBR) Earnings

  |   Expand Research on CSBR
Next EPS Date 12/15/26 EPS Growth Rate N/A
Average EPS % Beat Rate +1,137.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -5.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
12/15/26 Q227 N/A$0.02 N/A N/A$16.37M N/A N/A N/A
9/10/26 Q127 $0.05-$0.01 +$0.06$15.2M$15.05M N/A Details
7/27/26 Q426 N/A-$0.05 N/A $13.8M$12.89M N/A N/A N/A
3/12/26 Q326 $0.04$0.08 -$0.04$16.6M$16.43M N/A Details
12/15/25 Q226 N/A$0.01 N/A N/A$14.04M N/A N/A N/A
9/15/25 Q126 $0.02-$0.01 +$0.03$14M$14.7M N/A Details
9/10/25 Q126 N/A$0.06 N/A N/A$14.7M N/A N/A N/A
7/17/25 Q425 N/A$0.06 N/A N/A$15.7M N/A N/A N/A